AdjuTec Pharma and Venus Remedies Collaborate on Fighting Antimicrobial Resistance

Oslo, Norway, 5 February 2026 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces that Venus Remedies Ltd. (India) has successfully completed an in vitro susceptibility study using AdjuTec Pharma’s lead product APC301 in a collection of Indian multidrug-resistant pathogens.

AdjuTec Pharma and Venus Remedies share a joint mission to address the global health threat against Antimicrobial Resistant (AMR). AMR directly causes ∼1.3 million global deaths annually and is projected to cause ∼39 million accumulated global deaths by 2050. If left unchecked, AMR is poised to surpass the number of cancer deaths, posing a substantial threat to global health. In India, meropenem – a last resort antibiotic, reached a record low susceptibility of only 35% in Klebsiella pneumonia in 2024 (ICMR 2025). Unless immediate and more decisive actions are taken to address AMR, the global economy may suffer annual losses of $1.7 trillion by 2050 (World bank).

Full PR available here